The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.

Consumers who take GLP-1 drugs might switch what they eat, but they largely spend the same amount of money on CPG food and ...

Researchers documented a six per cent to nine per cent decline in grocery spending within the first six months of the GLP-1 ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Therapist Debby Parker tried to lose weight for years without success. Then she discovered an online weight management ...

Gemma said she’d decided to start taking medication - which is listed on Yazen’s website as GLP-1 weight loss injections - ...

A new report from AARP Public Policy Institute found that the top 25 drugs prescribed under Medicare Part D have nearly ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Her departure comes as the snacks maker faces challenges including higher cocoa costs, inflation that has curtailed product demand and the proliferation of GLP-1 weight-loss drugs.